A gene-targeted drug just reduced seizures by up to 91 percent in children with Dravet syndrome, a devastating genetic epilepsy that has left families desperate for solutions beyond failed medications.
Quick Take
- Zorevunersen, an experimental antisense therapy, reduced seizures from an average of 17 per month to near elimination in clinical trials of 81 children
- The drug targets the root cause of Dravet syndrome by boosting protein production from the healthy SCN1A gene copy, unlike current symptomatic treatments
- Results published March 4, 2026, in The New England Journal of Medicine show safety, tolerability, and early cognitive and behavioral improvements
- Phase 3 trials are now underway following three years of extension data demonstrating sustained seizure reduction and quality-of-life gains for families
The Burden of Untreatable Epilepsy
Dravet syndrome strikes infants without warning, triggered by mutations in the SCN1A gene that disrupts sodium channel function in the brain. The result is relentless, drug-resistant seizures that conventional epilepsy medications cannot control. Children endure dozens of seizures daily, developmental delays, movement disorders, and feeding difficulties. Parents live in constant fear. No disease-modifying therapy has ever existed until now. Current treatments merely mask symptoms without addressing the genetic foundation of the disease.
How Zorevunersen Works Differently
Unlike traditional seizure medications that suppress brain activity broadly, zorevunersen employs a precision approach called antisense oligonucleotide therapy. The drug targets the defective SCN1A gene and increases protein production from the healthy copy, restoring normal sodium channel function at the cellular level. Delivered via lumbar puncture at doses up to 70 milligrams, the treatment directly addresses the genetic malfunction rather than treating seizures as a symptom. This fundamental difference explains why families saw transformative results where previous medications failed.
The Clinical Trial Results
The international trial enrolled 81 children aged 2 to 18 years across specialized facilities in the United Kingdom and United States. At baseline, children experienced approximately 17 seizures per month. After treatment, seizure reduction ranged from 59 to 91 percent depending on dosing and individual response. Extension studies tracking 75 children over three years, with dosing every four months, sustained these dramatic improvements. Safety data revealed only mild side effects including headache, vomiting, and elevated cerebrospinal fluid protein levels—manageable compared to the seizure burden families previously endured.
Beyond Seizure Control
The trial documented improvements extending far beyond seizure reduction. Families reported enhanced quality of life, reduced caregiver burden, and early signs of cognitive and behavioral gains. One patient, Freddie, exemplified the transformation: he progressed from dozens of nightly seizures to just one or two brief episodes every three to five days. His mother, Lauren, described the experience as life-changing. These outcomes matter profoundly because Dravet syndrome’s developmental impact often proves as damaging as the seizures themselves. Restoring brain function at the genetic level opens possibilities for children to reach their developmental potential.
Global Impact and Rare Disease Hope
Dravet syndrome affects approximately one in 15,000 to 40,000 births globally, with particular burden in low and middle-income countries. India alone has 1 to 1.5 million children with epilepsy, including rare forms like Dravet. The broader epilepsy crisis affects 65 to 70 million people worldwide, yet treatment gaps remain especially severe for genetic forms. Zorevunersen’s success validates the antisense therapy approach for genetic epilepsies and signals that previously untreatable conditions may yield to precision medicine targeting the underlying genetic defect.
Phase 3 trials are now advancing to confirm efficacy in larger populations and establish the treatment pathway toward regulatory approval. For families living with Dravet syndrome, this represents the first genuine hope that their children might lead healthier, more normal lives. The disease that once seemed inevitably catastrophic now faces a targeted molecular solution.
Sources:
New drug cuts seizures by up to 91 percent in children with rare epilepsy
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
Life-changing drug identified for children with rare epilepsy
Life-changing drug identified for children with rare epilepsy
Drug breakthrough for children with severe form of epilepsy
